Oxford Centre for Diabetes, Endocrinology and Metabolism
OCDEM is a pioneering centre that combines clinical care, research and education in diabetes, endocrine and metabolic diseases. By promoting world-class research, we aim to enhance understanding of these diseases and to accelerate the search for new treatments and cures.
Head of OCDEM
-
David Ray
Professor of Endocrinology, Head of OCDEM, and Co-Director Sir Jules Thorn Sleep and Circadian Neuroscience Institute
History
Read about the beginnings of our centre.
Latest publications
-
Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis
Journal article
Coleman RL. et al, (2025), Cardiovascular Diabetology, 24
-
Melanocortin system activates carotid body arterial 1 chemoreceptors in hypertension
Journal article
Hodson D., (2025), Circulation Research
-
Clinical utility of self-reported sleep duration and insomnia symptoms in type 2 diabetes prediction.
Journal article
Wright AK. et al, (2025), Diabetologia
-
Best practice recommendations for the diagnosis and management of hypoparathyroidism
Journal article
THAKKER R., (2025), Metabolism: Clinical and Experimental
OCDEM is one of the largest dedicated research centres in diabetes, endocrinology and metabolism in Europe. Led by Professor David Ray, our work spans the spectrum of basic, translational and patient-orientated research. We are closely integrated with excellent clinical care for patients with diabetes, metabolic and endocrine conditions.
Areas of strength
- Type 2 diabetes including genomics, islet biology and function, novel therapeutics and large-scale clinical trials providing evidence for best practise
- Human integrative metabolic physiology
- Endocrine disorders such as glucocorticoid action, pituitary tumours and calcium homeostasis
Research Facilities
The Oxford BioBank is a resource for medical research to translate early discoveries into benefit for patients.
Funders
Our major funders include AstraZeneca, the European Commission, the Medical Research Council, Merck & Co and the Wellcome Trust.
